Lactobacilli-Fermented Chia Seeds as a Potential Anti-Hypertensive Agent.
H, A.S., J, C.G., FN, R.O., N, V.R., LE, G.D., M, R.G., & S, L.S. (2026). Lactobacilli-Fermented Chia Seeds as a Potential Anti-Hypertensive Agent.. Molecules (Basel, Switzerland). https://doi.org/10.3390/molecules31142427
H AS, J CG, FN RO, N VR, LE GD, M RG, et al. Lactobacilli-Fermented Chia Seeds as a Potential Anti-Hypertensive Agent.. Molecules (Basel, Switzerland). 2026; doi: 10.3390/molecules31142427
H AS, J CG, FN RO, et al. Lactobacilli-Fermented Chia Seeds as a Potential Anti-Hypertensive Agent.[J]. Molecules (Basel, Switzerland). 2026. DOI: 10.3390/molecules31142427.
@article{h2026,
author = {Atonal-Sánchez H and Cornejo-Garrido J and Rivera-Orduña FN and Villa-Ruano N and García-Díaz LE and Rangel-Galván M and Luna-Suárez S},
title = {Lactobacilli-Fermented Chia Seeds as a Potential Anti-Hypertensive Agent.},
journal = {Molecules (Basel, Switzerland)},
year = {2026},
doi = {10.3390/molecules31142427},
note = {PMID: 42513111},
}
TY - JOUR AU - Atonal-Sánchez H AU - Cornejo-Garrido J AU - Rivera-Orduña FN AU - Villa-Ruano N AU - García-Díaz LE AU - Rangel-Galván M AU - Luna-Suárez S TI - Lactobacilli-Fermented Chia Seeds as a Potential Anti-Hypertensive Agent. T2 - Molecules (Basel, Switzerland) PY - 2026 DO - 10.3390/molecules31142427 AN - PMID:42513111 ER -
Hypertension is a prevalent disorder that results in millions of deaths worldwide. In this regard, timely diagnosis and effective treatment are paramount for maintaining optimal blood pressure levels in the early stages of the disease. The objective of the present study was to synthesize and assess the effect of peptides derived from chia seeds that had undergone fermentation with Lacticaseibacillus paracasei strain 2501 (hereinafter referred to as LPDP, i.e., L. paracasei-derived products from this fermentation) on the angiotensin-converting enzyme (ACE) and the spontaneously hypertensive rat model (SHR). LPDP exhibited competitive inhibition, as evidenced by the identification of seven peptides in the <1 kDa fraction by HPLC-QToF-MS. The LPDP exhibited an IC50 of 11.1 μg/mL on ACE. The oral administration of 50 mg/kg body weight (BW) to SHR over a 14-day period resulted in a significant reduction in systolic pressure from 152 to 87 mmHg, accompanied by a substantial decrease in diastolic pressure from 117 to 74 mmHg. It is noteworthy that doses of 500 mg/kg BW led to a significant reduction in systolic pressure, from 154 to 68 mmHg and diastolic pressure, from 117 to 42 mmHg under identical experimental conditions. The hematological profiling of the assayed animals revealed that LPDP has no adverse effects at the cellular or biochemical level. These findings indicate the anti-hypertensive properties of LPDP and its possible application in the treatment of blood pressure.